DelveInsight’s, “Coronavirus-3C-like-Proteinase Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Coronavirus-3C-like-Proteinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Coronavirus-3C-like-Proteinase Inhibitors: Overview
The 3C-like protease (3CLpro), which hydrolyses viral polyproteins to produce functional proteins, is essential for coronavirus replication and is considered an important therapeutic target for diseases caused by coronaviruses, including COVID-19. Coronavirus 3CLpro is a cysteine protease that has two N-terminal domains containing two β-barrel chymotrypsin-like folds (8–10). The active site of 3CLpro is located in the cleft between the two domains and is characterized by a catalytic Cys-His dyad. Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.
The companies and academics are working to assess challenges and seek opportunities that could influence Coronavirus-3C-like-Proteinase Inhibitors R&D. The therapies under development are focused on novel approaches for Coronavirus-3C-like-Proteinase Inhibitors.
This segment of the Coronavirus-3C-like-Proteinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Coronavirus-3C-like-Proteinase Inhibitors Emerging Drugs
PF 07321332: Pfizer
PF-07321332 is a SARS-CoV-2-3CL protease inhibitor being developed by Pfizer. Pfizer recently initiated a trial to test PF-07321332 for the Prevention of COVID-19. The phase II/III Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis (EPIC-PEP) trial will test PF-07321332 in up to 2,660 adults aged 18 and older who live in the same household as someone with a confirmed symptomatic COVID-19 infection. It is also being evaluated in another trial of symptomatic, non-hospitalized adult patients with COVID-19.
S-217622: Shionogi
S-217622 is a 3CL protease inhibitor discovered by Shionogi. SARS-CoV-2 has an enzyme called 3CL protease, which is essential for the duplication of the virus. S-217622 suppresses the duplication of SARS-CoV-2 by selectively inhibiting 3CL protease. In non-clinical trials using SARS-CoV-2 infected animals, it has been confirmed that the viral load is rapidly and significantly reduced. In the Japanese phase 1 clinical trial that just started, we will confirm the pharmacokinetics, safety and tolerability of this drug in healthy adults.
Further product details are provided in the report……..
This segment of the report provides insights about the different Coronavirus-3C-like-Proteinase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the Coronavirus-3C-like-Proteinase Inhibitors. The companies which have their Coronavirus-3C-like-Proteinase Inhibitors drug candidates in the most advanced stage, i.e. Phase II/III include, Pfizer.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Coronavirus-3C-like-Proteinase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Coronavirus-3C-like-Proteinase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronavirus-3C-like-Proteinase Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Coronavirus-3C-like-Proteinase Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Coronavirus-3C-like-Proteinase Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III and II/III)
PF 07321332: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Pentarlandir: SyneuRx
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
S 217622: Shionogi
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
MPI 8: Sorrento Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Coronavirus-3C-like-Proteinase Inhibitors Key Companies
Coronavirus-3C-like-Proteinase Inhibitors Key Products
Coronavirus-3C-like-Proteinase Inhibitors- Unmet Needs
Coronavirus-3C-like-Proteinase Inhibitors- Market Drivers and Barriers
Coronavirus-3C-like-Proteinase Inhibitors- Future Perspectives and Conclusion
Coronavirus-3C-like-Proteinase Inhibitors Analyst Views
Coronavirus-3C-like-Proteinase Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Coronavirus-3C-like-Proteinase Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Coronavirus-3C-like-Proteinase Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Pfizer
• Shionogi
• SyneuRx International (Taiwan) corp
• AB Science
• Sorrento Therapeutics
• Acrivon Therapeutics
• Exscientia
• Arbutus Biopharma
• Cortexyme
• Aligos Therapeutics
• SOM Biotech
